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invasive epilepsy Surgery
Michael J. LaRiviere1 and Robert E. Gross2*
1 Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA, 2 Departments of Neurosurgery and 
Neurology, Emory University School of Medicine, Atlanta, GA, USA
Epilepsy is a common, disabling illness that is refractory to medical treatment in 
approximately one-third of patients, particularly among those with mesial temporal lobe 
epilepsy. While standard open mesial temporal resection is effective, achieving seizure 
freedom in most patients, efforts to develop safer, minimally invasive techniques have 
been underway for over half a century. Stereotactic ablative techniques, in particular, 
radiofrequency (RF) ablation, were first developed in the 1960s, with refinements in the 
1990s with the advent of modern computed tomography and magnetic resonance-
based imaging. In the past 5 years, the most recent techniques have used MRI-guided 
laser interstitial thermotherapy (LITT), the development of which began in the 1980s, 
saw refinements in MRI thermal imaging through the 1990s, and was initially used 
primarily for the treatment of intracranial and extracranial tumors. The present review 
describes the original stereotactic ablation trials, followed by modern imaging-guided 
RF ablation series for mesial temporal lobe epilepsy. The developments of LITT and MRI 
thermometry are then discussed. Finally, the two currently available MRI-guided LITT 
systems are reviewed for their role in the treatment of mesial temporal lobe and other 
medically refractory epilepsies.
Keywords: epilepsy, stereotactic, minimally invasive, laser ablation, magnetic resonance thermal imaging
iNTRODUCTiON
Epilepsy is a common neurological illness characterized by recurrent seizures. With an estimated 
lifetime prevalence of 3% and an often debilitating natural history (1), it is imperative that effective 
treatments are provided to minimize seizure burden and their medical, psychological, social, and 
economic implications. While first-line treatment of epilepsy draws from a broad pharmacopeia of 
anticonvulsant drugs (2), complete seizure control evades as many as one-third of medically treated 
patients (3). The International League Against Epilepsy task force defines drug-resistant epilepsy 
as lack of seizure freedom despite two separate antiepileptic drug regimens (4). Mesial temporal 
sclerosis (MTS), in particular, has been observed to be associated with drug resistance (5).
For these patients, surgery is highly effective in controlling and often abolishing seizures (5). 
The mainstay of surgical treatment has been open brain resection including anterior temporal 
lobectomy (ATL) and selective amygdalohippocampectomy (SAH), both of which include sev-
eral variant approaches (6–11). However, to further improve the safety profile of surgery (8), 
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over a half century of effort has been directed at developing 
minimally invasive surgical techniques for treating medically 
refractory epilepsy with defined epileptogenic foci. The pre-
sent review discusses the development of minimally invasive 
approaches, beginning with the original stereotactically guided 
ablation techniques, modern imaging-guided stereotactic 
radiofrequency (RF) ablation, and the emerging development 
of imaging-guided stereotactic laser ablation.
OPeN TeMPORAL LOBe ReSeCTiON
Open ATL has been a well-established treatment for over half a 
century (6, 7). Wiebe et al. demonstrated 64% seizure freedom 
at 1 year in operated patients (58% in the intent-to-treat surgery 
group, but which included several non-operated patients) in a 
randomized controlled trial of ATL vs. best medical therapy 
(9). A recent meta-analysis of 11 trials reported 1-year seizure 
freedom rates of 75% following ATL (n = 620) (note this and the 
numbers below from this study are a weighted average and can-
not be calculated simply from the numbers presented) (12). The 
subset with hippocampal sclerosis (AKA MTS) yielded higher 
rates (78%, n = 535). Similarly, although low accrual halted it 
prematurely, the recent early surgical therapy for drug-resistant 
temporal lobe epilepsy (ERSET) randomized controlled trial of 
ATL vs. continued medical therapy within 2 years of intractabil-
ity found that surgery yielded freedom from disabling seizures 
in 11 of 15 (73%) patients, as compared to 0 of 23 medically 
treated patients (10). While ATL does carry a risk of decline in 
verbal function such as naming, particularly with more exten-
sive lateral resections (11), on the whole it is relatively safe. The 
2001 randomized controlled trial underscores this point: with 
40 patients assigned to medical treatment and 40 assigned to 
surgery, the surgery group saw one postoperative stroke causing 
a neurologic deficit that fully resolved, one ventriculoperitoneal 
shunt placement for bleeding-induced communicating hydro-
cephalus, and no deaths (9). By comparison, the medical arm 
saw three episodes of status epilepticus in two patients, and 
one death due to presumed sudden unexplained death due to 
epilepsy (SUDEP) (9).
The advent of more selective approaches sparing resection of 
the anterior temporal lobe dates back to the mid-20th century 
(13–15), the goal of which is in part to minimize potential neu-
ropsychological impact from the temporal resection. Although 
seizure-free rates were long thought to be similar to ATL, the 
recent meta-analysis, which included 583 patients having under-
gone SAH, reveals a slightly lower effectiveness of 67% (n = 557), 
and 71% of those patients with MTS (n = 557) becoming seizure 
free (12). Statistically, for every 13 patients treated with SAH, 
one who would not become seizure free otherwise would with 
an ATL.
However, the question of whether selective AH spares neu-
ropsychological functions is not straightforward. On the basis of 
a large number of comparative (albeit non-randomized) studies, 
using various different measures over many years, Helmstaedter 
recently concluded that “selective surgery is clearly preferred 
(16).” As one example, patients with MTS undergoing left-sided 
ATL experienced decreased verbal learning as compared to SAH 
patients (while both experienced losses in long-term memory) 
(17, 18). However, selective approaches – while preserving tis-
sue, such as the temporal pole, from resection – subject fibers of 
passage to risk from dissection. In this regard, Helmstaedter, in 
a group of 97 seizure-free patients following either a temporal 
pole resection and AH vs. trans-Sylvian selective AH, found that 
verbal memory was better after left-sided temporal pole resection 
compared to trans-Sylvian selective AH, whereas on the right 
side, figural memory was better after the selective approach as 
compared to the temporal polar resection (19). While suggesting 
that the temporal pole and stem have distinctive roles in figural 
and verbal memory, respectively, the implication for open surgery 
is that compromise of neuropsychological functions can occur 
following both resective and dissective approaches through the 
temporal lobe during amygdalohippocampectomy. Helmstaedter 
(2013) concluded “no single surgical approach may be discerned 
to be the safest with regards to cognition, irrespective of seizure 
control. According to the surgical approach, different tissues and 
fiber tracts that hinder the surgical procedure or locate to adjacent 
areas may be affected and, either way, this has consequences for 
cognition (16).”
These effects on cognitive functions have, among other rea-
sons, and despite the satisfactory rate of seizure freedom, driven 
interest in minimally invasive techniques to further improve 
safety and tolerability of the surgery.
STeReOTACTiC ABLATiON
Original Trials
Initially mainly developed as a treatment for movement disor-
ders involving the basal ganglia (20), ablative techniques rely on 
stereotactic guidance to create a permanently destructive lesion. 
Whereas deep brain stimulation requires chronic implantation of 
electrodes (21–23), stereotactic ablation is an acute procedure that 
carries a lower risk of chronic complications, such as infection, 
than chronic instrument implantation. However, an advantage 
of deep brain stimulation is that stimulation can be adjusted or 
turned on and off.
Stereotactic ablation of epileptogenic foci was first described 
over 50 years ago by Narabayashi and colleagues in Tokyo (24). In 
a series of 60 patients, 46 of whom were diagnosed with epilepsy 
and 14 of whom had EEG disturbances or behavioral symptoms, 
the amygdala was stereotactically targeted using pneumoen-
cephalographic X-ray imaging and electrophysiologic recording 
for guidance. To confirm placement in the amygdala, the authors 
recorded the neuronal spike pattern upon giving the patient ether 
for olfactory stimulation. The target was ablated with an oil-wax-
lipiodol contrast dye mixture. Ultimately, they saw improvement 
in 85% (51/60) of patients, substantial improvement in 48% 
(29/60), and no change in only 3% (2/60). Morbidity was very 
low: one patient experienced a temporary palsy for 3 weeks and 
one patient developed several days of hypersexual behavior.
Despite this promising report, subsequent small trials in 
the 1960s yielded seizure freedom in just 19–30% of patients 
(Table 1) (25, 26). Notably, in this decade a −120°C cryoprobe 
was developed for stereotactic cryoablation of the amygdala, as 
reported by Heimburger et al. (26). Stereotactic ablation in the 
TABLe 1 | Summary of stereotactic ablation trials.
Study Seizure free improved only improved + seizure free Target
# Total % # Total % # Total %
Tokyo
Narabayashi et al. (24) – 60 – 51 60 85 51 60 85 A
Narabayashi and Mizutani (33) 9 25 36 8 25 32 17 25 68 A
Boston
Schwab et al. (25) 3 10 30 4 10 40 7 10 70 A
Paris
Talairach and Szikla (37) 9 14 64 2 14 14 11 14 79 AH
Freiburg, Germany
Umbach (38, 39) 5 18 28 11 18 61 16 18 89 AH
Bouchard and Umbach (29) – 50 – 33 50 65 33 50 65
wurzburg, Germany
Schaltenbrand et al. (36) – 5 – 3 5 60 3 5 60
indianapolis
Heimburger et al. (26) 4 21 19 12 21 57 16 21 76 A
Heimburger et al. (31) – 58 – 29 58 50 29 58 50
Copenhagen
Vaernet (40) 5 27 19 10 27 37 15 27 56 A
Bratislava, Slovakia
Nadvornik and Sramka (27) 5 8 63 3 8 38 8 8 100 H
Durham, NC, USA
Flanigin and Nashold (30) 4 16 25 6 16 38 10 16 63 AH
warsaw
Mempel et al. (41) 8 70 11 52 70 74 60 70 86 AH
Omaha, Ne, USA
Patil et al. (42, 43) – 3 – 3 3 100 3 3 100 AH
London, ON, Canada
Blume et al. (44) 6 14 43 4 14 29 10 14 71 AH
Parrent and Blume (34) 2 19 11 8 19 42 10 19 53
Birmingham, AL, USA
Kuzniecky and Guthrie (58) 3 8 38 4 8 50 7 8 88 HH
Tianjin, China
Yang et al. (45) 10 23 43 11 23 48 21 23 91 AH
Prague
Kalina et al. (46) 12 16 75 3 16 19 15 16 94 AH
Malikova et al. (48) 14 17 82 3 17 18 17 17 100 AH
Liscak et al. (49) 25 32 78 5 32 16 30 32 94 AH
Malikova et al. (50) 19 26 73 5 26 19 24 26 92 AH
Malikova et al. (52) 27 35 77 5 35 14 32 35 91 AH
Malikova et al. (53) 28 37 76 7 37 19 35 37 95 AH
Vojtech et al. (54) 43 61 70 6 61 10 49 61 80 AH
Niigata, Japan
Homma et al. (59) 3 5 60 2 5 40 5 5 100 HH
Kameyama et al. (60) 19 25 76 6 25 24 25 25 100 HH
Lyon, France
Catenoix et al. (47) 1 41 2 20 41 49 21 41 51 TL, PL, insula, SMA, OL, FL, 
C, PSC
visualase: Houston, TX, USA
Curry et al. (98) 5 5 100 – 5 – 5 5 100 MTL, FL, C, HH
Wilfong and Curry (117) 12 14 86 2 14 14 14 14 100 HH
Esquenazi et al. (125) 2 2 100 – 2 – 2 2 100 PVNH
NeuroBlate: St. Louis, MO, USA
Hawasli et al. (113) 1 1 100 – – – 1 1 100 insula
Beijing
Wu et al. (56) 4 7 57 0 7 0 4 7 57 MTL
(Continued)
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Study Seizure free improved only improved + seizure free Target
# Total % # Total % # Total %
Parma, italy
Cossu et al. (57) 16 89 18 9 89 10 27 89 28 TL, FCD, nodular heterotopy
visualase: Cleveland, OH, USA
Gonzalez-Martinez et al. (124) – 1 – – 1 – – 1 – PVNH
visualase: Atlanta, GA, USA
Willie et al. (99) 7 13 54 3 13 23 10 13 77 MTL
Willie and Gross (101) 5 5 100 – – – 5 5 100 MTL
McCracken et al. (132) 4 5 80 – – – 4 5 80 TL, OL, FL
visualase: Miami, FL, USA
Lewis et al. (129) 7 17 41 1 17 6 8 17 47 FCD, TS, HH, MTL, other
visualase: Philadelphia, PA, USA
Kang et al. (122) 14 20 70 4 20 20 18 20 90 MTL
A, amygdala; AH, amygdala-hippocampus; H, hypothalamus; HH, hypothalamic hamartoma; TL, temporal lobe; MTL, mesial temporal lobe; PL, parietal lobe; OL, occipital lobe; 
FL, frontal lobe; SMA, supplemental motor area; PSC, primary sensory cortex; C, cingulate; PVNH, periventricular nodular heterotopia; FCD, focal cortical dysplasia; TS, tuberous 
sclerosis.
TABLe 1 | Continued
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1970s produced seizure freedom rates as high as 63% in small 
series (27, 28), and rates of seizure improvement (including 
seizure freedom) ranged from 50 to 100% (27, 29–40). Although 
there was a paucity of published reports in the 1980s, one series 
of 70 patients undergoing medial amygdalotomy and anterior 
hippocampotomy1 found seizure improvement in 86%, including 
seizure freedom in 11% (41). Taken together, the early develop-
ment of stereotactic ablation saw a number of centers try several 
variations on the technique, with variable results. Later, develop-
ments in CT and MR imaging would allow for major improve-
ments in such minimally invasive treatments for epilepsy.
imaging Guidance for Radiofrequency 
Ablation
In 1995, image-guided targeting for epilepsy ablation was 
revolutionized with the report of the first CT-guided stereotactic 
amygdalohippocampotomy (42, 43). Two years later, Blume et al. 
reported a series of 14 patients with MRI targeting for RF ablation 
of the amygdala and hippocampus via a lateral (or orthogonal) 
approach. At 9–31  months follow-up, they reported that six 
(43%) were seizure free (after initial seizures in three), but they 
did not specify the length of time of seizure freedom. The results 
seemed to show a relationship to whether they performed conflu-
ent vs. discrete lesions (44). However, the subsequent report on 
the larger series of 19 patients in 1999 showed seizure freedom 
in just two patients (11%) (34). Whereas only one of five patients 
receiving discrete lesions (involving 13–21 mm, mean 16.8 mm, 
of hippocampus) experienced favorable seizure improvement 
(but not seizure freedom), 9 of 15 patients receiving confluent 
lesions (15–34  mm, mean 21.5  mm) experienced favorable 
outcomes; only two, however, became seizure free. Morbidity 
was very low, with just one patient developing an asymptomatic 
1 The term hippocampotomy will be used to denote ablation, whereas hip-
pocampectomy will be used to denote open resection.
hematoma along the electrode track. These reports suggested that 
RF ablation could be effective, but that greater extent of ablation 
was likely a critical factor.
In the next several years, different groups achieved highly 
variable results, ranging from 2 to 75% seizure freedom (45–47). 
Whereas Yang and colleagues reported 43% (10/23) seizure free-
dom (45), and Kalina et al. reported 75% (12/16) (46), Catenoix 
et al. felt that their 2% (1/41) seizure freedom was so disappoint-
ing that they recommended stereotactic ablation be used only 
when resection could not be performed (47). Importantly, unlike 
prior trials, Catenoix’s series showed that RF ablation could also 
be used to target structures in the neocortex.
Although some of these results were disappointing, recent 
work has rekindled interest in MRI-guided stereotactic RF abla-
tion. In a series of 17 patients, Malikova et al. achieved seizure 
freedom in 82% and improvement in the remaining 18% at 2-year 
follow-up (48). This group took an occipital approach to the 
long axis of the hippocampus and amygdala, and used a “string 
electrode” to perform radially distributed lesions. This allowed 
greater thermal coverage in the coronal plane as well as along 
the long axis: 16–38 lesions (median 25) produced ablations 
spanning 30–45  mm (median 35  mm) (49). Indeed, by using 
MRI to analyze the target structure’s size decrease following the 
procedure, they were able to correlate their imaging analysis 
with clinical outcome (48). Not surprisingly, they found that 
decreased amygdala–hippocampal volumes were associated with 
better seizure control. Subsequently, Liscak et  al. reported that 
among 51 patients, 78% achieved seizure freedom and 16% had 
seizure improvement over at least 2-year follow-up (49). Aside 
from such transient side effects as headache, meningitis, and 
upper meningeal syndrome [also seen in the authors’ prior trials 
(46, 48)], four patients developed hematomas, and one of these 
patients developed obstructive hydrocephalus that resolved with 
drainage. In 2011, Malikova et  al. reported seizure freedom in 
73% and seizure improvement in another 19% of 26 patients (50). 
Whereas Vojtech et al. in 2012 concluded that, among 31 patients, 
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RF amygdalohippocampectomy caused no significant deteriora-
tion in memory and cognitive parameters (51), Malikova et al., 
in that year, reported significant verbal and long-term memory 
improvements following ablation of right-sided lesions, with 
greater cognitive improvements seen with greater hippocampal 
volume reduction (52). In the latter study, they reported 77% sei-
zure freedom among 35 patients at 1 year. In 2013, Malikova et al. 
reported 2-year seizure outcomes among 37 patients, reporting 
76% seizure freedom (53). In contrast to their 2012 short-term 
data, in their 2013 work, they found significant improvements 
in global, verbal, semantic long term, and working memory, as 
well as delayed recall and attention in both right-sided and left-
sided lesions. The following year, Vojtech and colleagues reported 
long-term data for 61 patients with an average follow-up of over 
5  years, with 70% Engel class 1 (54). Reported adverse events 
included four hematomas, one case of hydrocephalus requiring 
shunt placement, three cases requiring open surgery, two patients 
who underwent repeat RF ablation, two patients with meningitis, 
and six new psychiatric diagnoses including one suicide. At the 
time of this publication, Malikova and colleagues’ most recent 
report in 2015 looked at cognitive outcomes in 37 patients treated 
with RF ablation (55). Whereas Malikova et  al. in 2012 found 
that better cognitive outcome correlated with increased right hip-
pocampus volume reduction (52), their 2015 paper showed worse 
verbal memory performance with increased left hippocampal 
reduction (the majority of these patients had Wada testing-
confirmed left-side speech and memory dominance). Taken 
together, these results suggest that the Prague center has been able 
to achieve seizure freedom in 70–82% of patients, and combined 
seizure improvement or freedom in 80–100% of patients (48–50). 
Clearly, these results were highly encouraging and have ignited 
renewed interest in stereotactic ablation (56, 57).
The past five decades of pioneering trials demonstrate the ver-
satility of stereotactic ablation. This technique is able to target not 
only the mesial temporal lobe but also other neocortical and deep 
brain structures (58–60), and it produces an immediate effect on 
seizure control. The variety of modalities tested to deliver the 
ablative lesion – oil-wax, cryoablation, and RF – suggests that 
future research with novel ablation techniques, coupled with 
advancements in MRI imaging, are likely to further refine target-
ing precision and protection of critical structures.
DeveLOPMeNT OF MRi-GUiDeD 
STeReOTACTiC LASeR iNTeRSTiTiAL 
THeRMOTHeRAPY
Laser interstitial Thermotherapy
In 1983, S. G. Bown published a seminal review surveying lasers 
used for tumor phototherapy (61). While most of the research until 
then had used CO2, argon, and neodymium:yttrium-aluminum-
garnet (Nd:YAG) external lasers, in his review, he also reported 
his original results from Nd:YAG interstitial laser ablation in an 
excised malignant melanoma model (61). By extrapolating the 
results of his prior external beam work, Bown hypothesized that 
interstitial laser ablation would fibrose, rather than perforate 
tissue (61, 62). Four years later, Matthewson et al. reported that 
interstitial Nd:YAG thermocoagulation in the rodent liver indeed 
yielded reproducible volumes of coagulative necrosis and devas-
cularization that were ultimately replaced by granulation tissue 
and fibrosis (63). With the goal of real-time imaging to further 
refine targeting, in 1989, Steger et al. used ultrasound in a series 
of five human patients with various extracranial tumors (64). This 
allowed them to visualize, in real-time, tumor necrosis resulting 
from their Nd:YAG laser ablation. Nd:YAG laser ablation was 
further tested in such sites as the canine prostate (65), rodent lung 
parenchyma (66), and human liver metastases (67).
In 1990, laser interstitial thermotherapy (LITT) was first 
reported for intracranial tumors, yielding 100% regression in five 
human patients with gliomas or brain metastases (68). Several 
other groups soon reported similar results in patients with grades 
II–III gliomas (69–71); postoperative MRI and histologic analysis 
revealed well-demarcated volumes of coagulative necrosis (70, 
71). As Roux, Bown, and colleagues reviewed in 1996, these 
histological findings are consistent with a pattern of tissue dam-
age unique to laser thermocoagulation: immediately adjacent to 
the Nd:YAG laser fiber, a small fibrin-filled cavity is surrounded 
by a larger volume of dense coagulation, itself encased in a shell 
of loose coagulation, ultimately transitioning to edema and then 
normal brain tissue (72). In a similar vein, Schwabe and col-
leagues defined five discrete regions by comparing pre-contrast 
T1-, post-contrast T1-, and T2-weighted MRI: a T2-intense 
catheter track, a T1 pre- and post-contrast-intense central zone, 
a T2-intense peripheral zone, a T1 post-contrast-enhancing 
peripheral zone border, and T2-intense surrounding edema (73). 
After nearly 4  years follow-up of 18 patients, they found that 
while laser ablation caused lesions initially to increase in size, they 
eventually lost half their volume in approximately 3 months and 
then exponentially decreased in size.
Ultimately, the first two decades of LITT saw the development 
of a potentially promising technique for both extracranial and 
intracranial tumors. But, its use in functional neurosurgery, for 
smaller targets near eloquent structures, would demand advances 
in real-time monitoring of tissue damage.
MRi Thermometry
The development of MRI thermal imaging (MRTI) began in 1988 
when Jolesz et al. used MRI to detect reversible tissue changes 
below 60°C, and coagulation from 60 to 100°C following laser 
ablation in the rabbit brain (74). It was later determined that 
temperatures between 45 and 90°C cause irreversible coagula-
tion, with cavity formation above 100°C (72, 75). On the other 
hand, Hayat and Friedburg found that tumor cells may be more 
thermosensitive, susceptible to damage at temperatures as low 
as 42.5–45.5°C (72, 76). Thus, the development of MRI thermal 
monitoring has sought to optimize measurement up through 
100°C, as well as in the sub-45°C range that may affect tumor 
cells but which critical structures must not exceed (77).
In 1991, Ascher and colleagues reported that real-time MRI 
could detect changes in tissue characteristics 3 min after initiating 
laser ablation in brain tumors (78). The following year, Fan et al. 
undertook a phase I clinical trial using real-time MRI thermom-
etry of Nd:YAG ablation in three patients with brain tumors 
(79). By first calibrating T1 signal change with probe-measured 
TABLe 2 | Comparison of radiofrequency ablation and MRi-guided laser 
interstitial thermotherapy.
RF ablation MRigLiTT
Target structures Can target deep  
structures
Can target deep  
structures
Temperature control Only at tip At tip and beyond
Visualization of lesion 
formation
No Yes
Lesion size Empirically determined Preplanned and 
adapted intraoperatively
Thermal spread Difficult to control Software controlled
Transition zone Large Small
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temperature change in laser-treated cadaver brains, MRI ther-
mometry could then be used with the three patients. However, 
this T1-based method was limited by a non-uniform RF field 
susceptible to external interference, potentially interfering with 
the accuracy of measured temperature change. A similar trial was 
later performed in eight patients, achieving reproducible changes 
in T1-weighted signal intensity during laser therapy (80). Here a 
T1-weighted 2D-fast low angle shot (2D-FLASH) sequence, with 
15 s acquisition time, delivered viewable images with a temporal 
resolution of 30 s. Signal changes were seen as early as 1 min, but 
again at an average of 3.1 min after the start of laser therapy. As 
one might expect, signal change evolution was different immedi-
ately adjacent to versus more peripherally around the laser fiber 
tip, reflecting differential tissue changes in these two zones (80), 
consistent with prior studies (72).
While other groups continued to use modified FLASH 
sequences for MRTI in LITT (81, 82), Fried et  al. (83) and 
Matsumoto et  al. (84, 85) used a different sequence to better 
monitor temperature in both phantoms and various animal 
tissues (83–85). In 1992, a T1-weighted rapid acquisition with 
relaxation enhancement (RARE) sequence was developed to 
achieve an improved temporal resolution of 16  s, temperature 
resolution of less than 6°C between pixels, and linear signal 
change from 10 to 50°C (85). Subsequently it was shown that, 
among T1-weighted sequences, fast spin-echo with a relaxation 
time (TR) of 100  ms delivered both improved temperature 
change sensitivity of less than 1.5% signal change per degree 
celsius, and acquisition time as fast as 5  s (84). Despite these 
advances in MRTI, thermotherapy-induced tissue change could 
still cause tissue-dependent signal change that would interfere 
with accurate temperature monitoring (83).
To address these limitations, water proton resonance frequency 
shift MRTI was developed (86), and this is the technique used 
with modern laser ablation systems (87–92). After demonstrat-
ing its feasibility in agarose gel phantoms with 0.2°C accuracy 
(86, 93), De Poorter et  al. applied the technique to human 
muscle in  vivo (93). In 1998, Kettenbach and colleagues built 
on this work by treating seven liver and three brain neoplasms 
using an MRI software interface to estimate temperature change 
in real time (77). They compared three techniques for estimating 
temperature and found that the above-described water proton 
chemical shift phase mapping (86, 93) proved to be the most 
sensitive technique for mapping temperature change (77). 
Eventually, various groups adopted the water proton chemical 
shift phase mapping technique (94–96), and this sequence 
would ultimately enable the development of such modern 
MRI-guided laser ablation systems as Visualase (87, 91, 92) 
and NeuroBlate (88–90).
MODeRN MRi-GUiDeD STeReOTACTiC 
LASeR iNTeRSTiTiAL THeRMOTHeRAPY 
SYSTeMS
Like RF ablation, MRI-guided LITT (MRIgLITT) is able to reach 
deep structures that would be inaccessible by open craniotomy 
and resection. Yet, compared with RF ablation, MRIgLITT has 
the advantages of real-time imaging and monitoring of thermal 
dose delivery using an Arrhenius equation-based model (92, 
97). Moreover, MRIgLITT can achieve a larger ablation volume 
that may require fewer probe targets and placements (Table 2). 
Disadvantages of this system are the potential for cerebrospinal 
fluid and blood flow to divert heat away from the target zone, 
although this is true for RF as well. However, users have felt that 
the ablation volume does adequately conform to the target lesion, 
and that encapsulated lesions seem to “contain” the heat (98, 99). 
MRIgLITT provides an unparalleled level of targeting precision: 
for instance, compared with open resection, MRIgLITT causes 
significantly less naming and object recognition decline (100), 
and repeat ablation in select patients with seizures refractory to 
initial laser ablation has been effective and well-tolerated (101).
Commercial LiTT Systems
Visualase
Visualase is an MRIgLITT system, FDA approved in 2007 “to 
necrotize or coagulate soft tissue through interstitial irradiation 
or thermal therapy under (MRI) guidance in… general sur-
gery,… neurosurgery,… and urology….” The Visualase Cooled 
Laser Applicator System (VCLAS) uses a saline-cooled catheter 
to deliver a fiber optic with a 3 or 10 mm diffusing tip (Figure 1). 
Saline coolant is circulated through the VCLAS by a peristaltic 
pump (Figure  2). Laser energy is delivered through a 15  W, 
980 nm diode laser, which is controlled via a user monitoring 
station that provides user-defined safety limits that trigger 
automatic laser shutoff when exceeded (Figure 2) (98). MRTI 
monitoring is provided in up to three planes, transferred to 
the monitoring station from the MRI by an FTP-like protocol 
(Figure  2) (92). The software uses an Arrhenius rate process 
model of thermal damage to depict the “irreversible damage 
zone” estimate, based on the time–temperature relationship (92, 
102). The software further allows for the definition of up to six 
user-defined thermal safety limits that, when reached, trigger 
automatic shutdown of the laser. Typically, three markers are 
placed near the laser fiber to prevent the temperature from 
exceeding 90°C, which could damage the fiber and/or lead to 
a steam event, and three markers are placed at nearby tissue at 
risk with a limit of ~50°C to prevent off-target thermal effects. 
The laser fiber assembly is typically implanted through a plastic 
or titanium anchor bolt (Figure  1A, inset) that is stereotacti-
cally implanted in the bone using one of a variety of stereotactic 
FiGURe 1 | visualase Cooled Laser Applicator System (vCLAS). (A) The cooled laser applicator. The ports are for inflow and outflow of saline coolant. Inset: 
titanium anchor for insertion. (B) VCLAS with 10 mm (top) and 3 mm (bottom) diffuser tips and simulated ablation zones. The VCLAS is a two-channel cannula: the 
optical fiber with diffuser tip is passed through the central channel, whereas the coolant circulates through the outer channel, as depicted in (C). Images provided by 
Medtronic, Louisville, CO, USA.
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techniques, either classic frame-based or more recent “frame-
less” techniques. After insertion of the cooling-cannula/laser 
fiber assembly, a planning MRI is used to select the target volume 
for ablation. The extent and temperature of the thermal delivery 
is assessed in near real time, after which contrast-enhanced 
T1 imaging, diffusion weighted imaging, and other protocols 
demonstrate the acute lesion volume (Figure 3) (98, 99).
McNichols and colleagues tested the Visualase system in 
porcine and canine brain models (92). By specifying temperature 
thresholds and their associated geometric volumes with real-time 
MRI imaging, they were able to define both a target for thermal 
ablation and critical structures that would be protected from 
high temperatures. The software feedback successfully achieved 
the desired temperatures in the ablation target, and the irrevers-
ible damage prediction models closely correlated with histologic 
findings.
NeuroBlate
NeuroBlate, originally called AutoLITT, is an MRIgLITT system 
that received FDA clearance in 2009 for intracranial and extrac-
ranial use (88). NeuroBlate uses a CO2-cooled catheter with a 
12 W, 1064 nm Nd:YAG laser (Figure 4). Initially, the system was 
only offered with a “side-fire” tip that ostensibly distributes the 
laser energy asymmetrically; it is now offered with a 10 mm dif-
fusing tip for more symmetric heating. The NeuroBlate software 
allows for preoperative designation of the target lesion with MR 
imaging and estimates thermal ablation volume intraoperatively. 
The system plans ablation on a slice-by-slice basis: once the laser 
is placed, intraoperative MRTI begins, the software appropriately 
orients the side-firing port, and thermal damage is monitored 
by the surgeon (Figure 5). Once ablation is complete on a given 
slice, the software robotically advances the laser probe to the 
next slice location, begins MRTI, plans ablation for that slice, 
and again orients and fires the laser. The system proceeds with 
this sequence until completion. Because this laser has a damage 
range of 1.5 cm, repeat placements are needed for targets larger 
than 3 cm (88).
CLiNiCAL OUTCOMeS USiNG 
COMMeRCiAL MRigLiTT
Clinical Outcomes Using Commercial 
MRigLiTT for Tumor Treatment
The first human application of the present systems was in six 
patients with brain metastases treated using the Visualase system 
(91). Perioperative morbidity was minimal, and no tumor recur-
rence was seen within the ablation zone at 3 months. Moreover, 
postoperative MRI showed that ablation lesions were consistent 
with preoperative planning to within 6 mm. Since then, several 
groups have used Visualase in the treatment of primary brain 
tumors (103–106), brain metastases, radiation necrosis (104, 
107–109), spinal metastases (110), and other tumors outside the 
CNS, most notably prostate cancer (111, 112). NeuroBlate was 
first trialed in 10 patients with recurrent glioblastoma (90) and 
has since been used in patients with primary gliomas (89, 113), 
FiGURe 2 | visualase workstation. (A) Entire workstation is shown, consisting of the computer and two monitors (at top), the 15 W, 980 nm diode laser (bottom 
right) and the peristaltic pump for the saline coolant (bottom left). (B) The top monitor screen is shown and magnified in (C), with the axial image plane being 
visualized. The screen can be quickly toggled between two or three chosen image planes, as desired; moreover, one plane can be visualized on the top monitor and 
concurrently a different one on the bottom monitor. The left side of the top monitor is a sliding window that can depict the four types of information being acquired all 
at once: phase image (arrow), i.e., “thermal map”; magnitude image (#) – a rapidly acquired but low-resolution anatomical image from the same sequence (fast 
spoiled gradient echo, SPGRE) that produces the phase image; irreversible damage zone estimate (arrowhead), calculated from the Arrhenius equation; and 
high-resolution anatomical image (*) in same plane as the phase image, acquired prior to the phase mapping. Also shown in sliding window are temperatures of the 
user-defined safety points. Images provided by Medtronic, Louisville, CO, USA.
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brain metastases (113, 114), and radiation necrosis (115, 116). 
Further discussion is beyond the scope of this review.
Clinical Outcomes Using Commercial 
MRigLiTT for epilepsy Treatment
Curry et  al. published the first experience with MRIgLITT in 
epilepsy in five pediatric patients in 2012 (98). Epileptogenic foci 
included one tuberous sclerosis (TS) lesion in the cingulate gyrus, 
one cortical dysplasia in the frontal lobe, two hypothalamic 
hamartomas, and one patient with both a sclerotic mesial temporal 
focus and a superior temporal neurocysticercosis calcification. In 
three of the five patients, the target lesion was completely ablated. 
All were seizure free at the last follow-up (2–13 months) but only 
two had reached 12  months – the “gold standard” (cingulate 
FiGURe 3 | visualase ablation. Left, target region in the hippocampus, with Visualase cooling catheter laser applicator in place. Center, irreversible damage zone 
estimate (red) during the laser ablation. Right, post-ablation contrast-enhanced T1 image depicting the actual damage zone surrounded by region of blood–brain 
barrier breakdown (contrast enhancement).
FiGURe 4 | NeuroBlate catheter. (A) The AXiiiS stereotactic miniframe is attached to the skull with spikes and bone screws. (B) The NeuroBlate 12 W, 1064 nm 
Nd:YAG laser delivery probe has a depth stop adjustment with a locking interface. (C) The SideFire fiber emits laser energy through a clear sapphire lens at a 78° 
angle. CO2 gas cools the tip and the thermocouple transmits temperature data to the M*Vision software. FullFire diffusing, rather than directional, tip available (not 
shown). ©Monteris Medical. Used by permission. The use of any Monteris Medical photo or image does not imply Monteris’ review or endorsement of any article or 
publication.
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FiGURe 5 | NeuroBlate software. The M*Vision software allows the target volume to be contoured slice-by-slice, thermal dose threshold lines are calculated, and 
the laser probe trajectory can be planned. After planning, the software executes the treatment allowing the user to monitor real-time thermal imaging. Laser 
adjustments can be made during treatment. Once the ablation is complete, MR images are obtained and compared with thermal dose thresholds. ©Monteris 
Medical. Used by permission.
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TS, MTLE). The published experience, which now covers a fair 
number of cases of various etiologies, will be discussed.
Hypothalamic Hamartomas
Following their initial report (98), Wilfong and Curry (117) 
published a series of 14 pediatric patients with hypothalamic 
hamartomas (HH) treated with MRIgLITT, achieving seizure 
freedom in 86% of patients at a mean of 9  months follow-up 
(range 1–24). Notably, safety was excellent with one patient expe-
riencing an asymptomatic subarachnoid hemorrhage, and with a 
median length of stay of 1 day. Zubkov et al. reported a single case 
of a disabling amnestic syndrome following laser ablation of a 
HH in a 19-year old with a prior right temporal lobectomy (118). 
Post-ablation imaging showed edema in the bilateral mammil-
lary bodies, which likely contributed to the deficit, although the 
role of the prior lobectomy is uncertain. Given the invasiveness 
of alternative therapies such as open resection (119) and delay 
to effectiveness and possible radiation-induced adverse effects 
from stereotactic radiosurgery (120), this is an important new 
treatment modality for this indication, but should be judiciously 
applied and studied.
Mesial Temporal Lobe Epilepsy
Outcomes
Willie et al. reported the use of MRIgLITT to perform stereotac-
tic laser amygdalohippocampotomy (SLAH) in 13 adult patients 
with mesial temporal lobe epilepsy (99). Seven patients (54%) 
were seizure free at 5–26 months follow-up, and an additional 
three (23%) had seizure reduction. With the exception of one 
patient with an acute subdural hematoma that was evacuated 
without sequelae, given a lack of postoperative symptoms in 
the first three patients, the remaining patients did not require 
postoperative ICU care, and overall median hospital length 
of stay was just 1 day. Subsequently, Waseem et al. compared 
SLAH in seven patients >50 years of age to outcomes after SAH 
in seven patients (121). Four of the five SLAH patients with 
outcomes reported at 1  year or more were seizure free (they 
did not report the outcome on the other two patients), and 
all of the seven SAH patients were seizure free. Interestingly, 
although use of pain medications and length of hospitalization 
were less in the SLAH patients, hospital and surgery costs were 
significantly greater in the MRIgLITT procedure compared to 
the open procedure.
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More recently, Kang et  al. reported the outcome of 20 
patients: similar to our series, 8 of 15 (53%, 95% CI 30.1–75.2%) 
with follow-up at ≥6 months were seizure free after 6 months; 
one of the non-seizure-free patients had a low-grade glioma in 
the temporal lobe and arguably should be excluded from this 
analysis (122). With low numbers, their reported outcome at 
1 year was not as good (4 of 11, 36.4%, 95% CI 14.9–64.8%), 
but 3 of 5 patients at 2 years (60%, 95% CI 22.9–88.4%) were 
seizure free. An analysis of outcome as a function of ablation 
volume was non-significant – not surprising, given the small 
numbers. Patients were discharged home after 1 day (n = 17) 
or 2 days (n = 3) with only one patient staying in the intensive 
care unit (1 day).
The above seizure freedom rates approach but do not match 
those of the gold-standard open ATL. It is therefore important to 
note that SLAH does not preclude further surgery. In situations 
of recurrent seizures in the setting of technical failure to achieve 
a complete ablation of mesial temporal structures, a repeat SLAH 
can be performed. This was done in two cases in Willie et  al. 
(99): one did not become seizure free whereas the last patient in 
that report had been seizure free at 4 months following the repeat 
ablation, and has remained seizure free subsequently. We have 
re-ablated nine patients of whom four have become seizure free. 
In the setting of recurrent seizures after a technically successful 
SLAH, or repeat SLAH, open resection can be performed. Two 
patients reported on by Willie et al. (99) underwent ATL, one of 
whom became seizure free, whereas Kang et al. (122) reported 
four patients, three of whom became seizure free after ATL. 
While the mesial structures have been ablated, leaving only some 
or all of the parahippocampal structures (both ATL and SAH) 
and other lateral temporal structures (ATL) to be resected, it is 
important to remove any remnant mesial temporal tissue that 
may persist. This portion of the operation is challenging due 
to the disturbed anatomy and requires an in-depth knowledge 
of mesial temporal anatomy.
Complications after SLAH for MTLE
Of the 13 patients reported by Willie et  al., complications 
included one patient with persistent homonymous hemianopia, 
likely secondary to catheter misplacement, and one patient with 
a small acute subdural hemorrhage that resolved with evacua-
tion (99). Two of the seven SLAH patients reported by Waseem 
et  al. experienced a partial visual field deficit, and one patient 
had a postoperative seizure requiring hospital admission (121). 
One patient had an extended postoperative headache. Of the 20 
patients reported by Kang et al., one (the 20th) had a hematoma 
and edema at the left mesial temporal ablation site and an incon-
gruous superior quadrantanopsia at 2.5 months follow-up (122). 
One other had a transient 4th nerve palsy with vertical diplopia. 
Headache was observed in four patients. Notably, one patient 
with a previous history of chronic depression and suicidal idea-
tion, who was not seizure-free following the ablation, committed 
suicide 4.4 months following the procedure.
Neuropsychological Outcomes after SLAH for MTLE
Drane et  al. evaluated the temporal lobe functions of nam-
ing and recognition of common nouns and famous persons, 
functions increasingly being recognized as affected by temporal 
lobe surgery, in patients following SLAH (n = 19) as compared 
to open resections, including both selective AH and temporal 
lobectomy (100). Naming and recognition declines were signifi-
cantly greater in those patients undergoing open resections (32 
of 39; dominant: 21 of 22; non-dominant: 11 of 17) as compared 
to those undergoing SLAH, where none of the 17 patients 
declined. Kang et  al. examined six patients after a median of 
10.2  months following SLAH, five of whom had dominant 
ablations (122). By contrast, there was a statistically significant 
decline in total learning on the California Verbal Learning Test 
(CVLT), with three patients – all dominant – considered to have 
significant decline. Strikingly, there was no change in CVLT 
delayed recall and no change on the Wechsler Memory Scale 
(WMS) logical memory (LM) I and II tests, in which up to 37% 
of patients undergoing ATL would be expected to decline (123). 
The authors hypothesize that contextual memory tested in the 
WMS LM task is less affected by SLAH due to the preservation of 
lateral temporal lobe language processes, as observed by Drane 
et al. (100), which support semantic aids to memory acquisition 
in this task. In contrast, the non-contextual processes tested in 
the CVLT, not aided by semantic context, reveal more the effects 
of SLAH directly on the hippocampus. Finally, Waseem et  al. 
found clinically meaningful improvement in the delayed verbal 
memory performance in two of four patients tested, and decline 
in one of four (121), using the Rey Auditory and Verbal Learning 
Test. Thus, overall SLAH seems to preserve lateral temporal lobe 
processes as compared to open surgery – i.e., it minimizes col-
lateral damage – while possibly having less impact on memory 
as well. Further research to address effects on memory perfor-
mance is required, as well as the clinical impact of preserved 
lateral temporal lobe functions.
Malformations of Cortical Development  
and Glial-neuronal Tumors
Periventricular Nodular Heterotopia
Laser ablation of periventricular nodular heterotopias (PVH) 
has been reported in four patients (124–126). Among the three 
patients with reported follow-up data, one achieved seizure 
freedom with medication adjustment at 12  months (125), one 
was seizure free after 8 months (126), and one achieved seizure 
freedom with subsequent temporal lobectomy and amygdalohip-
pocampectomy (125). Nevertheless, PVHs are surgically difficult 
to access, and laser ablation provides a useful tool for their treat-
ment in the instances where the PVH, rather than the overlying 
cortex, is determined to be involved in the seizure onset zone. 
Laser ablation is particularly useful when functional tissue pre-
cludes safe open access to the lesion or its network. In one case, 
the location was in the posterior frontal region on the dominant 
side, and the PVH was involved at onset; the patient became 
seizure free with ablation of the PVH alone, without complica-
tion (125). In another case, there were bilateral onsets from PVHs 
that extended from the periventricular region into the occipital 
lobes, surrounded by cortical tissue activated by visual fMRI and 
by optic radiation fibers, as determined by diffusion tensor imag-
ing (126). Laser ablation allowed focal destruction of the PVH 
bilaterally, with temperature monitoring of surrounding tissue at 
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risk, and the patient became seizure free without visual deficits 
on field testing. This simply would not have been possible with 
an open approach.
Focal Cortical Dysplasias and Glial–Neuronal Tumors
Focal cortical dysplasias (FCDs) are common surgical targets that 
are amenable, in many cases, to open surgical resection. There 
was a single FCD case in Curry et al.’s initial series, with outcome 
only at 3 months (98). Bandt and Leuthardt noted a patient with 
a temporal lobe FCD who was seizure free for 18  months fol-
lowing laser ablation with NeuroBlate (127), and Buckley et al. 
noted a patient with occipital DNET, proven pathologically at 
the time of the laser ablation, who was seizure free for 6 months 
(128). The largest series is that of Lewis et al. (129), who reported 
laser ablation in 17 pediatric patients, including 9 patients with 
FCD: they included, among these, 2 patients with biopsy-proven 
gangliogliomas. One difficulty in determining pathologic-related 
outcomes is that biopsies are either not performed routinely 
during the LITT procedure, or if they are, they suffer from 
sampling bias. Five of the nine with FCD did have pathologically 
proven Palmini type Ia, IIa, or IIb FCD. Of the nine, only three 
became seizure free at follow-up periods ranging from 12.6 to 
35.9 months, and two of these three had pathologically proven 
gangliogliomas. Thus, the outcome of MRIgLITT for FCDs, as 
performed by Lewis et al. (129), is substantially worse than from 
open surgical resections (130), likely exemplifying the empirical 
observations that complete resection of the seizure onset zone, 
defined electrographically, is the most important predictor of 
seizure outcome (131). Perhaps, a more aggressive approach in 
the future will yield superior outcomes.
Lewis et  al. reported complications in four patients, includ-
ing catheter misplacement in two, edema in one, and cooling 
failure causing catheter damage in one patient (129). In one of 
the patients with catheter misplacement, hemorrhage and hydro-
cephalus required the placement of a temporary drain, after which 
the hydrocephalus subsequently resolved. Following catheter 
damage in one patient, ablation was prematurely discontinued, 
and the catheter tip was left in the parenchyma. Despite these 
complications, length of stay was just 1 day in 11/17 patients.
Tuberous Sclerosis Complex
Curry et al. reported one patient with tuberous sclerosis who was 
seizure free at 13 months following MRIgLITT (98). Included in 
the series of Lewis et al. (129) were four patients with definitive 
tuberous sclerosis, of whom two became seizure-free at 3.5 and 
9.6  months, likely too early to draw conclusions. While this 
pathology seems well suited to focal ablative therapy, as in the 
case of FCD, it is possible that undertreatment of the lesions 
in these cases has contributed to the limited results thus far.
Cavernous Malformations
In a recent series of five patients with epilepsy caused by cavernous 
malformations, McCracken et al. found that 4/5 (80%) achieved 
Engel class I seizure freedom at mean 17.4  months follow-up 
(132). Importantly, no complications occurred, and length of stay 
was less than 36 h in all patients.
Other Focal Epileptic Lesions
Using the NeuroBlate system, Hawasli and colleagues were 
able to achieve seizure freedom for over 4  years after ablation 
of a 5.8  cm3 insular focus at an area of a previously silent 
infarction; the ictal onset zone was identified with depth 
electrodes (113, 127, 133). The patient had postoperative mild 
speech and memory deficits requiring cognitive rehabilitation. 
Similarly, Bandt and Leuthardt ablated an MRI-negative, depth 
electrode-identified insular focus, achieving seizure freedom 
for 6  months, with a mild postoperative hemiparesis (127). 
They also performed laser ablation of the left basal temporal 
cortex adjacent to an encephalocele concordant with scalp EEG 
monitoring. In this case, no invasive monitoring was performed, 
and the patient has been seizure free for 2  years with a single 
minimally invasive procedure.
CONCLUSiON
In the treatment of medically refractory mesial temporal lobe 
epilepsy, minimally invasive techniques have seen both revolu-
tionary and evolutionary changes over the past half century. The 
development of more precise stereotactic ablation techniques 
and advances in imaging modalities have provided improved 
guidance and targeting, while MRI thermometry revolutionized 
intraoperative monitoring of ablation. The more recent introduc-
tion of laser interstitial thermal therapy offers tighter thermal 
control, and the combination with thermal MRI imaging allows 
the surgeon to protect critical structures from damage. The use 
of laser ablation for MTS is only in its infancy, but its superior 
targeting and intraoperative feedback control makes it an exciting 
candidate for further investigation. A prospective trial comparing 
MRI-guided stereotactic laser ablation with open mesial tempo-
ral lobectomy would be instrumental in demonstrating the safety 
and efficacy of this promising new technique for the treatment 
of epilepsy, but FDA approval of the technology in the US and 
its widespread availability makes this very difficult, as patient 
and physician acceptance has been rapid. Other clinical trial 
approaches will be necessary to demonstrate relative effectiveness 
and safety with respect to standard open resection techniques. 
However, it must be considered that the comparison of minimally 
invasive techniques is not solely to standard open techniques but 
also to continued medical therapy, as there is a significant number 
of patients – and referring physicians – who consider the risk, 
discomfort, or inconvenience of conventional resective surgery 
preclusive.
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